Pregnancy-Related Venous Thromboembolism Risk Perception and Prevention in Risk-Averse Times-Significant Change Required: a Commentary.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40400112.
- Also identified by DOI 10.1111/1471-0528.18229 and PMC identifier 12315063.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Between 2020 and 2022 in the United Kingdom (UK), there were 45 maternal deaths from venous thromboembolism (VTE), out of more than 2 million maternities. This occurred despite extensive risk assessment and prescribing of low molecular weight heparin (LMWH) thromboprophylaxis, alongside clinicians' overestimate of risk and commitment to the cause. Whilst every maternal death is a tragedy, the challenge ahead is immense-to identify, in an efficient and consistent way, those few women at risk of life-threatening thrombosis, and then minimise that risk with a cost-effective therapy that is acceptable to pregnant and postpartum women, and does not do more harm than good. We propose a way forward.
Medical subject headings
- Venous Thromboembolism
- Anticoagulants
- Pregnancy Complications, Cardiovascular